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Abstract
Background: Dengue cases have been classified according to disease severity into dengue fever (DF) and dengue
hemorrhagic fever (DHF). Although DF is considered a non-severe manifestation of dengue, it has been recently
demonstrated that DF represents a heterogeneous group of patients with varied clinical complications and grades
of severity. Particularly, bleeding complications, commonly associated to DHF, can be detected in half of the
patients with DF. Although a frequent complication, the causes of bleedings in DF have not been fully addressed.
Thus, the aim of this study was to perform a comprehensive evaluation of possible pathophysiological mechanisms
that could contribute to the bleeding tendency observed in patients with DF.
Methods: This is a case–control study that enrolled adults with DF without bleeding and adults with DF and
bleeding complications during the defervescence period. Healthy controls were also included. Peripheral blood
counts, inflammatory, fibrinolysis and endothelial cell activation markers, and thrombin generation were evaluated
in patients and controls.
Results: We included 33 adults with DF without complications, 26 adults with DF and bleeding and 67 healthy
controls. Bleeding episodes were mild in 15 (57.6%) and moderate in 11 (42.4%) patients, 8 (30.7%) patients had
bleedings in multiple sites. Patients with DF and bleedings had lower platelet counts than DF without bleeding
(median = 19,500 vs. 203,500/mm3, P < 0,0001). Levels of TNF-α, thrombomodulin and VWF were significantly increased
in the two dengue groups than in healthy controls, but similar between patients with and without bleedings. Plasma
levels of tPA and D-dimer were significantly increased in patients with bleedings (median tPA levels were 4.5, 5.2,
11.7 ng/ml, P < 0.0001 and median D-dimer levels were 515.5, 1028 and 1927 ng/ml, P < 0.0001). The thrombin
generation test showed that patients with bleeding complications had reduced thrombin formation (total thrombin
generated were 3753.4 in controls, 3367.5 in non-bleeding and 2274.5nM in bleeding patients, P < 0.002).
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Conclusions: DF can manifest with spontaneous bleedings, which are associated with specific coagulation and
fibrinolysis profiles that are not significantly present in DF without this complication. Particularly, thrombocytopenia,
excessive fibrinolysis and reduced thrombin formation may contribute to the bleeding manifestations in DF.
Keywords: Acquired coagulation disorders, Fibrinolytic disorders, Thrombin generation, Infectious diseases, Dengue fever,
Dengue hemorrhagic fever, Thrombocytopenia
Background
Dengue is caused by a common arthropod-born virus with
worldwide distribution. It is estimated that 50 million indi-
viduals are infected annually and 2.5 billion live in endemic
areas [1]. Dengue is a febrile illness, with non-specific
clinical manifestations that include fever, headache and
myalgia, known as dengue fever (DF) [2]. Some patients,
however, can manifest a severe form of the disease charac-
terized by plasma leakage, thrombocytopenia, bleedings
and shock, denominated dengue hemorrhagic fever (DHF)
[3-7]. Although associated with DHF, bleeding complica-
tions may also occur in cases of DF [8]. In fact, it is esti-
mated that about 50% of patients with DF can present
bleeding episodes [9]. However, in contrast to patients with
DHF, bleeding manifestations in patients with DF occur in
the absence of plasma leakage [3,10]. Yet, the pathogenesis
of bleeding complications in DF has not been fully
addressed.
The aim of this study was to evaluate possible
pathophysiological mechanisms that contribute to
bleeding complications in adults with DF. We performed a
comprehensive evaluation of hemostasis in a well-selected
population of adults with DF, with and without bleeding
manifestations. Particularly, the evaluation of blood
coagulation included the thrombin generation test (TGT),
a global hemostasis assay that mimics the physiological
process of coagulation and is more specific to deter-
mine the integrity of clot formation [11]. Markers of
fibrinolysis, inflammation and endothelial activation
were also evaluated.
Methods
Study design and patients selection
This is a case–control study that included patients with
suspected dengue infection with bleeding complications
and patients without bleeding complications. Patients
were selected during distinct outbreaks of dengue in
the cities of Rio de Janeiro and Campinas, Brazil, in
2 different hospitals and 3 primary care medical
centers. The study duration was from January 2008
until May 2011, but patients were included mainly
in 2008 and 2010, when two important dengue out-
breaks occurred in the Southeast Brazil, particularly
in Rio de Janeiro and in Campinas, respectively.
According to the Brazilian Ministry of Health the
predominant circulating dengue serotype was DENV-2 in
that period.
The inclusion criteria for the group with bleeding
complications were suspected dengue infection, age over
17 years old, presence of spontaneous bleeding and being
in the defervescence period. For the group without bleeding
complications, the inclusion criteria were suspected dengue
infection, age over 17 years old, no spontaneous bleeding
and being in the defervescence period. The defervescence
period was detected according to the medical follow-up at
the primary care medical centers or at the hospitals; it was
determined as the period when the body temperature
tended to diminish. Usually, patients were enrolled
for the study on the day they were tested for dengue
serology (after the 5th day of fever), according to the
Brazilian Ministry of Health protocol. Patients who met
the inclusion criteria were reported to the study personnel
who evaluated if the patients could be enrolled for the
study. After the enrollment, patients were followed-up
prospectively until recovery.
Exclusion criteria were the same for both groups: chronic
kidney or liver disease, autoimmune or chronic infectious
disease, hematological disorders and neoplasia. Pregnant
women were excluded. Patients who lost follow-up after
the enrollment were excluded. When the serology results
were available, patients with negative anti-dengue IgM were
excluded.
The serological tests for the detection of anti-dengue
virus IgM and IgG antibodies were performed by
enzyme-linked immunosorbent assay (ELISA) and were
conducted at the referral laboratories of public heath.
Patients with positive anti-IgM were diagnosed with
dengue. All confirmed or discharged cases of dengue
infection were in accordance with the disease notification
by the official health authority.
The positive serological anti-dengue IgM test was used
to confirm dengue diagnosis because the high sensibility
of this test, above 80%, after the 5th day of symptoms.
Also, the sensibilities of the virus antigen isolation or the
virus acid nucleic detection by PCR are lower at the
defervescence period, when our patients were enrolled
for the study. In the Southeast Brazil other flaviviruses
are not endemic and the population is not immunized
against yellow fever virus, so the specificity of dengue
serology is high.
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Three hundred and nineteen (319) adult patients were
attended with suspected dengue infection in the period of
the study, 63 patients were in the hospitals because of
complications and 256 were attended in the primary care
medical centers. From the 63 patients with complications
attended in the hospitals, we were able to include in the
study 40 patients because 3 had other complications than
bleedings, 6 refused to participate and 14 had signs of
convalescence (bleeding cessation and platelet arise).
Anti-dengue IgM was positive in 34 out of 40 patients
with bleeding complications included. From those, 8 were
classified as dengue hemorrhagic fever, so 26 patients with
dengue fever and spontaneous bleeding were included for
the final analyses. From the 256 patients attended in the
primary care centers, 178 patients were not enrolled for
the study because they were in the febrile phase of dengue,
did not collect anti-dengue serology or lost the follow-up.
One patient had chronic myeloid leukemia, one patient
had previous history of idiopathic thrombocytopenic
purpura, three patients had chronic kidney disease, 18
refused to participate and five blood samples arrived in the
laboratory after 2 hours from the blood collection, they
were all excluded from the study. From the 50 patients
included, 33 had positive anti-dengue IgM (Figure 1).
Healthy volunteers matched to patients by gender, age,
ethnicity and ABO blood group were selected from the
community as a control group. Exclusion criteria used
for controls were equal to those used for patients.
The study was conducted in compliance with the
Helsinki Declaration. This study was approved by the
Research Ethics Committee of the School of Medical
Sciences of the University of Campinas (UNICAMP)
and was registered in the Brazilian National System
of Information about Research Ethics (SISNEP) under
the number CAAE = 0170.0.146.000-08 (http://portal2.
saude.gov.br/sisnep/). A written informed consent was
obtained from patients, or their attending relatives,
and from controls.
Patients’ clinical evaluation
Patients were prospectively evaluated by the same physician
until they recovered from symptoms. Clinical evaluations
and serial blood counts were perfomed from the
enrollment day to the convalescence period to detect
the changings in platelet counts and hematocrit. Previous
blood counts from the febrile phase were retrospectively
collected and used as basal parameters. The decreasing
body temperature was evaluated clinically. Clinical and
epidemiological data were recorded in a structured study
form. Patients in the febril phase or in convalescence were
not selected for the study.
Dengue cases were classified according to the World
Health Organization (WHO) [7], by two different expert
physicians, into DF or DHF. The following exams were
performed for DHF diagnosis: serial hematocrit, chest
X-ray, ultrasound and serum albumin levels. Blood
counts were performed daily for inpatients and at intervals
depending on the clinical course for outpatients. Chest
X-ray, ultrasound and albumin were performed once
during the hospitalization period. All patients with
complicated dengue were hospitalized. Patients who
were diagnosed with DHF on the day of the enrollment or
during the follow-up were further excluded from the
analysis, in accordance with our aim to evaluate only
patients with DF (Figure 1).
Bleeding episodes were classified as mild, moderate and
severe; this classification was adapted from WHO’s defini-
tions [1]. Petechiae, ecchymosis and gingivorrhagia were
considered mild bleeding symptoms. Bleeding episodes of
gastrointestinal (GI) or genitourinary (GU) tracts were
considered moderate. Bleeding episodes accompanied by
hemodynamic instability were classified as severe bleedings.
Laboratory procedures
Three tubes of blood samples were obtained from the
participants at the time of their enrollment for the study.
Selection of patients 
without
bleeding complications
Selection of patients with
bleeding complications
*Patients with DHF were excluded from the final analysis
Figure 1 Flow chart of the study.
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Two citrate and one EDTA-containing tubes were
collected and samples were immediately centrifuged.
Serum and platelet-poor plasma (PPP) obtained were
separated and stored at −80°C within two hours from
the collection. Control samples were processed following
the same protocols and by the same investigator.
Markers of inflammation and endothelial cells activation
Serum levels of tumor necrosis factor (TNF)-α were
performed to evaluate the degree of inflammatory
activation. Plasma levels of thrombomodulin (TM)
and von Willebrand factor (VWF) were evaluated as
markers of endothelial activation. Commercial ELISA
kits were used to determine serum levels of TNF-α
(Quantikine HS, R&DSystems, Minneapolis, USA) and
plasma levels of TM (Imunobind Trombomodulin ELISA
kit, American Diagnostica INC, Stamford, USA). VWF
antigen (VWF-Ag) levels in plasma were measured by
ELISA as previously described [12].
Fibrinolysis pathways
Specific markers of fibrinolysis, such as tissue plas-
minogen activator (tPA), D-dimer and plasminogen
activator inhibitor (PAI-1) were measured. Commercial
ELISA assays were used to determine the plasma levels of
D-dimer (IMUCLONE™ D-dimer, American Diagnostica
INC, Stamford, USA), tPA (IMUBIND® tPA, American
Diagnostica INC, Stamford, USA) and PAI-1 (PAI-1,
American Diagnostica INC, Stamford, USA).
Thrombin generation test
Blood coagulation was evaluated by TGT in PPP using a
commercial fluorescent assay (Technothrombin® TGA,
Technoclone GmbH, Vienna, Austria) and fluorescence
was read using FLx800 Fluorescence Microplate Reader
(Bio-Tek Instruments, Winooski, USA). Four parameters
of TGT were evaluated: the lag phase, which is the time
from the beginning of the experiment to the first burst
in thrombin formation, the thrombin peak, which is
the maximum concentration of thrombin formed, the
velocity-index, which is the amount of thrombin formed
per minute and the total thrombin formed, represented by
area under curve (AUC).
Statistical analysis
Categorical variables were compared using Chi-square
or Fisher exact test. To compare continuous variables
between two groups Wilcoxon-Mann–Whitney test was
used. To compare continuous variables among three or
more groups Kruskal-Wallis analysis was used, followed by
Tukey test to identify the differences, when necessary. The
Spearman rank correlation was used to determine the cor-
relation between variables. Multiple logistic regression and
ROC curve were performed to identify variables associated
to bleeding tendencies and to estimate optimal cut-off
values, respectively.
Data were analyzed using SPSS for Windows version
10.0 (SPSS Inc, Chicago, IL, USA) and SAS System for
Windows version 9.2 (SAS Institute Inc, Cary, NC, USA).
Graphics were made using GraphPad Prism, version 4 for
Windows (GraphPad Software Inc., La Jolla, CA, USA).
P <0.05 was considered statistically significant.
Results
Twenty-six adults with DF and spontaneous bleeding
complications, 33 adults with DF without spontaneous
bleeding and 67 healthy controls were included in the
study. Eight patients had DHF and were excluded from
the analysis. Twelve patients (20.3%) presented positive
anti-dengue IgG serology.
Demographic parameters such as age, gender, ethnicity
and ABO blood group were similar between patients and
controls (Table 1). The most common commorbidity was
hypertension, reported by 9 patients; patients with severe
commorbidities were excluded.
Patients without bleeding complications were treated in
the primary care medical centers where daily medical
examination was performed and periodic blood counts
obtained. In these centers, patients were treated with oral
or parenteral hydration. Those with bleeding complica-
tions were hospitalized. Bleeding episodes were mild in 15
(57.6%) patients and moderate in 11 (42.4%) patients.
Eight (30.7%) patients had bleedings in multiple sites.
There were no severe bleedings. Patients with mild
bleeding had predominantly disseminated ecchymosis
and petechiae (n = 8), gingivorrhagia (n = 5) and epistaxis
(n = 2). Patients with moderate bleeding had predominantly
hypermenorrhea (n = 4), hematuria (n = 3), melena (n = 2),
hemoptysis (n = 1) and hematemesis (n = 1). Only one
patient received platelet transfusion. No other patient
received blood transfusions. No hemostatic agents were
administrated to the patients. Patients were mainly treated
with crystalloids replacement. Table 2 contains the detailed
clinical presentation of all patients.
Blood count parameters
Platelets and monocytes counts were significantly altered
among patients with bleedings (Figure 2). Median platelet
counts were 203,500/mm3 (range 77,000-479,000/mm3)
in patients without bleedings and 19,500/mm3 (range
3,000-58,000/mm3) in patients with DF and bleedings
(P < 0.0001). Median monocytes counts were 497/mm3
(range 203-2320/mm3) in patients without bleedings and
1,320/mm3 (range 496-2597/mm3) in patients with
bleedings (P < 0.0001). The degree of thrombocytopenia
was statistically correlated to the degree of monocytosis
(r = −0.45, P < 0.0001).
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Median hemoglobin levels were within the normal
range among patient groups and there was no difference
in hematocrit levels (median values = 43% vs. 43% in
non-bleeding vs. bleeding patients, P = 0.48).
Inflammatory and endothelial cell activation markers
Serum levels of TNF-α, plasma TM and VWF were
increased in DF patients compared to controls. However,
the levels of these markers were similar between
non-bleeding and bleeding patients (Figure 3).
Markers of fibrinolysis activity
D-dimer and tPA levels were significantly increased in
patients with bleedings. Median D-dimer levels were
515.5, 1028 and 1927 ng/ml in controls, non-bleeding and
bleeding patients, respectively (P < 0.0001). Median tPA
levels were 4.5, 5.2, 11.7 ng/ml in controls, non-bleeding
and bleeding patients, respectively (P < 0.0001) (Figure 4).
Plasma PAI-1 levels were similar among controls and DF
groups (data not shown).
Thrombocytopenia was significantly correlated to
higher D-dimer (r = −0.47, P < 0.0001) and tPA levels
(r = −0.49, P < 0.0001) in patients.
Blood coagulation parameters
Patients presented normal, or slightly altered, aPTTand PT.
Median aPTT was 30.3” (range 27.5” – 47.5”) and median
PT was 14.4” (range 13 – 24”). TGT was performed in 18
patients with DF (9 with bleedings and 9 without) and 24
controls. The first consecutive patients included in each
group were selected for TGT analysis. All TGT parameters
were significantly impaired in patients with bleedings,
compared to controls. Particularly, decreased values
of thrombin peak and AUC were observed in patients
with bleedings (P = 0.014 and P = 0.008, respectively),
suggesting that the thrombin formation is decreased
in these patients (Table 3).
Evaluation of independent parameters associated with
bleeding tendencies
Using a multivariate logistic regression analysis, throm-
bocytopenia (OR = 200; 95%CI = 22-1000; P = 0.0003),
monocytosis (OR = 13,5; 95%CI = 3,0-48,6; P < 0.0001) and
elevated D-dimer (OR = 14,9; 95%CI = 2,4-90; P = 0.0032)
were the strongest parameters associated to bleeding
complications in DF.
ROC curve analysis showed that the cut-off values
that better discriminated cases of DF with bleeding
Table 1 Demographic data of patients and controls
Demographic data Controls (n = 67) DF without bleeding (n = 33) DF with bleeding (n = 26) P
Female/Male (n) 35/32 13/20 15/11 0.32
Age (median and range), years 38.5 (19–76) 39 (17 – 71) 41 (20 – 79) 0.45
Caucasian/Afrodescendent (n) 38/29 24/9 12/14 0.11
ABO “non-O”/ ABO “O” (n) 36/31 19/14 10/16 0.30
This table shows the demographic parameters, as gender, age, ethnicity and ABO blood group evaluated in patients and controls.
Table 2 Clinical presentation of patients with dengue fever
Clinical presentation Patients with DF without bleeding (n = 33) Patients with DF with bleeding (n = 26) P
Days with symptoms, median (range) 7 (5–10) 7 (2–15) 0.68
Days in the hospital, median (range) 0 2 (1–10) N.A.
Fever 33 (100) 26 (100) N.A.
Headache 17 (51.5) 22 (84,6) 0.01
Prostration 20 (60.6) 24 (92,3) 0.006
Nausea or Vomiting, n (%) 11 (33.3) 13 (50) 0.28
Abdominal pain, n (%) 3 (9) 12 (46) 0.002
Liver enlargement, n (%) 0 2 (7.7) N.A.
Hypotension, n (%) 0 2 (7.7) N.A.
Syncope, n (%) 0 2 (7.7) N.A.
Acute renal insuficiency, n (%) 0 1 (3.8) N.A.
Signs of plasma leakage, n (%) 0 0 N.A.
Shock, n (%) 0 0 N.A.
N.A. = not aplicable.
This table shows patients’ symptoms and signs of dengue at the first clinical evaluation or during the follow-up.
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complications were platelets < 67,000/mm3 (P < 0.0001,
94% sensitivity and 93% specificity) and monocytes >
715/mm3 (P < 0.0001, 84% sensitivity and 82% specificity).
Discussion
In this study, patients with dengue that did not fulfill the
WHO criteria of DHF, and could otherwise be considered
as having a non-severe form of the disease, indeed
presented bleeding episodes and needed special medical
care for that. This observation highlights that patients with
DF can present bleeding complications and reinforces the
importance of a detailed clinical evaluation of these patients
in order to deliver appropriate care. Nowadays, efforts have
been done to implement a new dengue classification,
capable to identify signs of potential severe manifestations
of the disease [1,2,8,10,13-16]. This new classification, how-
ever, is based only on clinical evaluations, many parameters
are subjective and the varied mechanisms responsible for
each detected complication are not fully understood.
Understanding these mechanisms could promote the early
identification of patients with severe disease and ultimately
improve diagnostic and therapeutic strategies, thus limiting
morbidity and mortality.
Bleeding complication is the most common complication
reported in patients with DF. Particularly, adult patients
may present more bleeding manifestations than children
[17], and the bleeding manifestations in adults may occur
in the absence of plasma leakage [18]. These observations
raise at least two questions: first, that bleeding manifesta-
tions and plasma leakage may be two independent compli-
cations of dengue. Second, that the dengue hemorrhagic
fever classification may underestimate some severe
cases of dengue. In this study, we focused on evaluating
the bleeding complication in adults with DF.
Thrombocytopenia has been considered as an important
factor responsible for bleeding events in DHF [19] and as
a common laboratory changing of DF [2,17]. The present
study showed that thrombocytopenia was strongly associ-
ated with bleeding complications; raising the hypothesis
that thrombocytopenia is not only a laboratory changing
in DF but also an important cause of bleeding. Many
factors can contribute to the onset of thrombocytopenia
in DF, from a reactive immune response against the plate-
lets to decreased platelet production [20-23], however the
evaluation of the causes of thrombocytopenia is beyond























Figure 2 Peripheral blood counts. This figure illustrates the presence of thrombocytopenia (a) and monocytosis (b) in patients with bleeding
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Figure 3 Inflammatory and endothelial activation markers. This figure illustrates the activation of the inflammatory response and the
endothelial cells in dengue patients. Levels of inflammatory and endothelial cells activation markers were similar between DF groups. a. TNF-α, b.
plasma TM levels. c. VWF antigen. These parameters were performed in all patients. P values were calculated using the Kruskal-Wallis analysis,
followed by the Tukey post-test. CT = controls . * Place of differences detected by Tukey post-test.
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monocytosis was also observed in patients with DF and
bleedings.
Our results have demonstrated, as well, that the
levels of TNF-α, TM and VWF were similar among
DF patients, regardless of the presence of bleeding
complications. These results were different from those
previously described in DHF. Clinical studies have
shown that markers of inflammation and endothelial
cells activation may be increased in patients with
DHF [5,24]. Indeed, the activation of the endothelial
cells, by the virus or by inflammation, seems to be
the initial pathogenesis of DHF [25]. Endothelial activation
may be responsible for plasma leakage and shock [25-29].
However, our findings suggest that inflammation and
endothelial cells activation may not be associated with
bleeding complications of DF. Possibly, the fact that
our patients with bleeding complications did not have
an overt plasma leakage syndrome may explain the
lack of increased inflammation and endothelial activation
found in these patients, compared to those without
bleedings.
On the other hand, excessive fibrinolysis was associ-
ated with bleeding complications in our patients with
DF, since plasma levels of tPA and D-dimer were
significantly increased in these patients. In a similar
way, previous studies have demonstrated that patients
with DHF may also present with excessive fibrinolysis
[4,5,30-32]. It has been controversial, however, whether
the stimulus for fibrinolysis in dengue was secondary to a
disseminated intravascular coagulation (DIC) [4,17,33].
We failed to detect signs of DIC in patients with DF
and bleedings. All blood smears from these patients
were analyzed and none presented schistocytes. Results
of aPTT and PT were within the normal range or only
slightly increased. Furthermore, thrombin generation
was reduced in patients with DF and bleeding.
Indeed, the finding of decreased thrombin generation
is interesting since, to our knowledge, this coagulation
abnormality has not been confirmed in dengue before.
The relationship between dengue and activation of
coagulation pathways is controversial [31]. Prolonged
aPTT was demonstrated in some but not all clinical
studies [4,9] while PT and thrombin time seem to
remain unchanged [9]. We could confirm, by TGT,
that the coagulation in patients with bleedings was
impaired and the thrombin generation was decreased.
































Figure 4 Fibrinolysis parameters. This figure illustrates the presence of hyperfibrinolysis in dengue patients. Fibrinolysis activity markers, such as
tPA and D-dimer, were particularly elevated in patients with DF and bleeding complications. a. tPA levels; b. D-dimer levels. These parameters
were performed in all patients. P values were calculated using the Kruskal-Wallis analysis, followed by the Tukey post-test. CT = controls. * Place
of differences detected by Tukey post-test.
Table 3 Thrombin generation test
TGT Controls (n = 24) DF without bleeding (n = 9) DF with bleeding (n = 9) P #
Lag phase * 9.1 (1.8-17.7) 12.3 (3.1 -17.1) ± 11.6 (3.1 – 22.6) ± 0.021
Thrombin peak (nM) * 338.7 (145.1 - 512.2) 251.6 (70.7 – 432.3) 199.0 (15.9 – 394.1) ± 0.009
Velocity-index * 59.1 (13.3 – 128.7) 37.3 (6.7 – 193.2) 32.8 (12.6-73.0) ± 0.033
AUC * 3753.4 (2228.9–4905.6) 3367.5 (1512.9-4284.2) 2274.5 (180.5-3829.2) ± 0.002
* Median and range.
# P values were calculated using the Kruskal-Wallis analysis.
± Tukey test detected places of differences. In lag phase the differences were in DF with and also in DF without bleeding vs. controls. In thrombin peak, velocity
index and AUC the difference was significant in the DF with bleeding group vs. controls.
This table shows the TGT results in controls and patients with DF, according to the presence of bleeding manifestations.
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Clinical studies that evaluated the TGT in patients
with chronic liver disorder demonstrated that, besides
the prolonged aPTT and PT, the thrombin generation
was normal [34]. The authors hypothesized that the
decreased activity of the natural anticoagulants might
compensate the impaired activity of coagulation factors
in these patients, promoting thus a normal thrombin
formation [35]. It is possible that a similar mechanism
may happen in dengue and the activity of natural antico-
agulants may be important in determining the thrombin
formation. It has been shown previously that the activity
of coagulation factors seem to remain within the normal
range [33], although the activity of natural anticoagu-
lants may be altered in some cases of dengue [5,30].
Plasma TM is a molecule that contributes to the activa-
tion of C protein [36], thus the increased levels of
plasma TM observed in our patients with dengue could
contribute to the activation this natural anticoagulant.
Furthermore, it has been recently demonstrated that
DV could bind directly to prothrombin and inhibit its
activation to thrombin [37]. Regardless of the cause
of the coagulopathy, our study showed that the co-
agulation activity may be decreased during dengue
infections and that this disorder may be associated
with bleeding complications.
Our results have demonstrated not only that cases of
DF can manifest with spontaneous bleedings, but also
that these cases may be accompanied by changes in
peripheral blood counts, coagulation and fibrinolysis that
may be not significantly detected in DF without this
complication. In regard of bleeding complications, these
results are consistent with the new concept that DF
represents a clinically heterogeneous group of patients
and also raise the hypothesis that different pathological
mechanisms may be present in these patients. These
findings corroborate the importance of the revision of
dengue classification proposed by WHO in 2009.
It is important, also, to point out some limitations that
may be found in this study. It is possible that some
results have been influenced by the selection process
and the sample size. This is a case–control study and
patients were included as they presented or not the
outcome of interest. However, a great number of
patients could not be enrolled; this posed a problem to
the selection process because some patients with
possibly important clinical manifestations may have been
missed. Of note, all patients with bleeding complications
were selected from the hospitals and presented poten-
tially severe manifestations of dengue, less severe cases
were not detected among patients with bleedings.
Because of that, it is possible that the severity of the
coagulopathy associated with DF with bleedings may
have been overestimated. This may also explain that,
although being small, the sample size had enough power
to show some differences in coagulation and fibrinolysis
markers, particularly the profound differences in platelet
counts observed between bleeding and non-bleeding
patients. On the other hand, the careful selection
approach warranted the standardization of the period of
the disease analyzed and the well characterization of the
groups. Another potential limitation is the fact that the
dengue groups came from different medical settings.
However the patients represent the same population,
their follow – up and treatment were performed
according to the WHO recommendations regardless of
where they were treated. Although this study is not a
controlled clinical trial, the methodology for patients’
diagnosis and classification used in this study reflects
the medical care on dengue in the real world.
Because of that, this study raises problems on dengue
risk stratification that appear in the current clinical
practices. Also, this study demonstrated some labora-
tory abnormalities that could be detected during the
patients’ regular follow-up. The evaluation of patients
in a real world set, without the need to follow a strict
agenda of tests as in the controlled clinical trials, may
represent an advantage because it allows the detection of
laboratory changes that might possibly be reproduced in
the clinical practice.
Moreover, our findings reflect dengue presentation
and treatment in Brazil. The clinical presentation of
dengue might be slightly different in Latin America
than observed in Southeast Asia, because of the importance
of non-dengue hemorrhagic fever syndromes for disease
morbidity [8,16]. Therefore, our findings may raise
important informations since the risk stratification of
dengue has been reevaluated in order to englobe the
disease presentation worldwide.
Finally, even with these limitations, our results
highlighted that patients classified as dengue fever may
present a complex coagulopathy and that the traditional
dengue classification may not identify cases with
laboratory abnormalities associated with potentially
severe forms of the disease.
Conclusions
Bleeding complications in patients with DF were associ-
ated with thrombocytopenia, reduced thrombin forma-
tion and increased fibrinolysis activity. The identification
that some patients with DF may present with a complex
coagulopathy reinforces the heterogeneity of this group
and the necessity for new strategies to better stratify the
severity of the disease for clinical and epidemiological
purposes. Furthermore, understanding the bleeding
disorders associated with dengue could lead to new
diagnostic and therapeutic strategies in DF, since,
until recently, bleeding manifestations had been studied
mainly in patients with DHF.
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